Insured Fertility Care in Japan: Can Universal Coverage Preserve a Single-Embryo-Transfer Culture?

Japan has one of the world's lowest fertility rates, and assisted reproductive technology (ART) now accounts for a substantial and growing share of Japanese births. In early 2022, general infertility treatment, ART, and male infertility treatment were incorporated into Japan's universal health insurance, replacing a means-tested subsidy and largely self-funded model with insured care at a fixed coinsurance rate. The insured pathway is bounded by an upper age limit for initiating treatment, caps on the number of covered embryo transfers that tighten with age, and the prohibition on mixed billing except for designated advanced medical care. This narrative review examines the early clinical implications of the reform for practicing obstetrician-gynecologists by describing national ART outcomes before and after coverage using the Japan Society of Obstetrics and Gynecology (JSOG) registry and placing Japanese practice in an international context. Relevant literature and registry data were identified by searching PubMed and Google Scholar together with the primary Japanese registry and policy sources and the major international ART registries. In the two years after coverage began, registered cycles and ART-derived neonates rose to successive record highs, and access broadened particularly among younger patients, while Japan's characteristic profile of minimal stimulation, freeze-all with frozen-thawed embryo transfer, and predominant single embryo transfer (SET) was largely maintained. However, the overall SET rate declined, and multiple pregnancies increased in the first full insured year, particularly among older patients; these findings are consistent with, but do not prove, a possible incentive effect of fixed transfer caps. Internationally, conventional fresh-cycle live-birth metrics are difficult to interpret for Japan because of its practice pattern and older patient population, whereas its multiple-birth rate remains among the world's lowest. For clinicians, the priorities of the insured era are to raise the age-43 timeline early, defend elective SET near coverage limits, and make explicit the mixed-billing trade-offs of non-covered options such as preimplantation genetic testing (PGT).